КОПАКСОН®
A Multinational, Multicenter, Randomized, Parallel Group, Double Blind, Placebo Controlled Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate 20mg/0.5ml New Formulation Administered Daily by Subcutaneous Injection
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT01578785/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine); clinmarket. Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–55 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 120 чел. в стране «Беларусь».
- Центров в реестре: 7 в 4 городах. Список — ниже на странице.
- Плановая дата окончания (11.2012) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 12 · невключение: 18
Критерии включения
- Subjects must meet all inclusion criteria in order to be eligible for the study:
- Subjects must have a confirmed and documented multiple sclerosis (MS) diagnosis as defined by the 2010 Revised McDonald criteria \[Ann Neurol 2011: 69:292-302\], with a relapsing-remitting disease course.
- Subjects must be ambulatory with a Kurtzke's Expanded Disability Status Scale (EDSS) score of 0-5.5 in both screening and baseline visits.
- Subjects must be in a relapse-free, stable neurological condition and free of corticosteroid treatment \[intravenous (IV), intramuscular (IM) and/or by mouth (PO)\] or ACTH (adrenocorticotropic hormone) 30 days prior to screening (Month-1) and between screening and baseline (Month 0) visits.
- Subjects must have experienced one of the following:
- At least one documented relapse in the 12 months prior to screening,
- At least two documented relapses in the 24 months prior to screening,
- One documented relapse between 12 and 24 months prior to screening with at least one documented T1-Gd enhancing lesion in a magnetic resonance imaging (MRI) performed within 12 months prior to screening.
- Subjects must be between 18 and 55 years of age, inclusive.
- Women of child-bearing potential must practice an acceptable method of birth control \[acceptable methods of birth control in this study include: surgical sterilization, intrauterine devices, oral contraceptive, contraceptive patch, long-acting injectable contraceptive, partner's vasectomy or a double-barrier method (condom or diaphragm with spermicide)\].
- Subjects must be able to sign and date a written informed consent prior to entering the study.
- Subjects must be willing and able to comply with the protocol requirements for the duration of the study.
Критерии невключения
- Any of the following conditions will exclude the subject from entering the study:
- Subjects with progressive forms of MS.
- Use of experimental or investigational drugs, and/or participation in drug clinical studies within the 6 months prior to screening.
- Use of immunosuppressive agents (including Mitoxantrone and Fingolimod) or cytotoxic agents within 6 months prior to the screening visit.
- Use of natalizumab (Tysabri®) or any other monoclonal antibodies within 2 years prior to screening.
- Use of cladribine within 2 years prior to screening.
- Previous treatment with immunomodulators \[including IFNβ 1a and 1b, and IV Immunoglobulin (IVIg)\] within 2 months prior to screening.
- Previous use of glatiramer acetate (GA) or any other glatiramoid.
- Chronic (more than 30 consecutive days) systemic (IV, PO or IM) corticosteroid treatment within 6 months prior to screening visit.
- Previous total body irradiation or total lymphoid irradiation.
- Previous stem-cell treatment, autologous bone marrow transplantation or allogenic bone marrow transplantation.
- Pregnancy or breastfeeding.
- Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation, as determined by medical history, physical exams, ECG, abnormal laboratory tests and chest X-ray. Such conditions may include hepatic, renal or metabolic diseases, systemic disease, acute infection, current malignancy or recent history (5 years) of malignancy, major psychiatric disorder, history of drug and/or alcohol abuse and allergies that could be detrimental according to the investigator's judgment.
- A known history of sensitivity to Gadolinium.
- Glomerular filtration rate (GFR) ≤ 60 mL/minute at the screening visit
- Inability to successfully undergo MRI scanning.
- A known drug hypersensitivity to Mannitol.
- Subjects who underwent endovascular treatment for chronic cerebrospinal venous insufficiency (CCSVI).
Источник: ClinicalTrials.gov, NCT01578785 · запись обновлена в реестре 2 апреля 2014.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 3
- The Annualized Relapse Rate During the Placebo Controlled Period — Day 1 up to Month 12
Цель исследования
Оценить эффективность, безопасность и переносимость инъекционного ежедневного введения новой формуляции глатирамера ацетата (ГА), 20 мг/0,5 мл, путем подкожных инъекций (п/к) пациентам с рецидивирующим ремитирующим рассеянным склерозом (RRMS).
Где проходит
7 центров в 4 городахОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT01578785 Официальный реестр (США) · загружено 9 ноября 2026Название, сроки
-
clinmarket · № 10665 Каталог исследований · загружено 1 октября 2026Препарат, номер протокола, цель, разрешение, фаза, статус, число участников, лекарственная форма, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.